一项试点外基因组测序研究表明,生殖系变异会影响局部骨髓瘤儿科患者的甲状腺素诱导毒性
Francesca Minnai1,2, Sara Noci3, Nunzia Mangano3
1Institute for Biomedical Technologies, National Research Council, Segrate (MI), Italy.
Pediatric blood & cancer
|June 20, 2023
概括
遗传变异会影响患有骨肉瘤的儿童对化疗的反应. 这项研究确定了与不良事件相关的基因组,这表明药物基因发现的更广泛的基因组方法.
科学领域:
- 基因组学就是基因组学.
- 儿科瘤学 儿科瘤学
- 药物遗传学 药物遗传学
背景情况:
- 在儿科患者中,骨髓瘤 (OS) 治疗反应显著变化.
- 遗传遗传变异越来越多地被认为是这种可变反应的贡献者.
- 以前对儿科OS遗传因素的研究已经产生了不一致的结果,并且经常检查有限的基因组.
研究的目的:
- 识别与不良事件的个体差异相关的生殖系编码变异.
- 为了研究患者对甲状腺素,青和多克索鲁比辛化疗的反应.
- 探索局部骨髓瘤治疗变异性的遗传基础.
主要方法:
- 在24名儿科骨髓瘤患者中进行了一项外体全域关联研究.
- 使用SNP-Set (Sequence) 内核关联测试 (SKAT),优化用于小样本大小.
- 分析了与中性质衰减和肝毒性等不良事件的关联.
主要成果:
- 鉴定了与甲状腺素诱导的中性质减退和肝毒性相关的显著基因组 (FDR < 0.05).
- 一些已识别的基因位于以前与类似的表型相关的区域 (例如白细胞计数,性酸酶水平).
- 这项试点研究突出了超越传统药物代谢和运输类别的潜在药物基因.
结论:
- 需要在更大的队列和功能性研究中进一步验证.
- 这项研究支持对全基因组变异的调查,以在骨髓瘤中发现新的药物基因.
- 研究结果表明,在儿童癌症中,化疗反应的变异性具有更广泛的遗传基础.
相关概念视频
01:07Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
01:20Mismatch Repair
4.9K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.9K
01:25Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K